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Long noncoding RNAs (lncRNAs) significantly influ-
ence the development and regulation of genome
expression in cells. Here, we demonstrate the role of
lncRNA ceruloplasmin (NRCP) in cancer metabolism
and elucidate functional effects leading to increased
tumor progression. NRCP was highly upregulated in
ovarian tumors, and knockdown of NRCP resulted in
significantly increased apoptosis, decreased cell pro-
liferation, and decreased glycolysis compared with
control cancer cells. In an orthotopic mouse model
of ovarian cancer, siNRCP delivered via a liposomal
carrier significantly reduced tumor growth compared
with control treatment. We identified NRCP as an in-
termediate binding partner between STAT1 and RNA
polymerase II, leading to increased expression of
downstream target genes such as glucose-6-phos-
phate isomerase. Collectively, we report a previously
unrecognized role of the lncRNANRCP in modulating
cancer metabolism. As demonstrated, DOPC nano-
particle-incorporated siRNA-mediated silencing of
this lncRNA in vivo provides therapeutic avenue to-
ward modulating lncRNAs in cancer.
INTRODUCTION
Noncoding RNAs (ncRNAs) have been shown to play a signifi-
cant role in cancer development and progression. These RNAsCell Repare divided into multiple families based on their sizes and
biogenesis pathways (Mattick and Makunin, 2006; Mercer
et al., 2009; Wang and Chang, 2011). Members of one ncRNA
family, long ncRNAs (lncRNAs), are genomically transcribed
noncoding transcripts longer than 200 nucleotides (Mattick
and Makunin, 2006; Mercer et al., 2009). Many lncRNAs are
differentially expressed in different tissues and under different
developmental and pathological conditions, suggesting that
they play important biologic roles (Wang andChang, 2011; Estel-
ler, 2011; Prensner and Chinnaiyan, 2011; Cheetham et al.,
2013). lncRNAs are involved in modulation of cellular functions
via regulation of transcription, epigenetic modulation, and
enhancement of RNA degradation (Mercer et al., 2009; Wang
and Chang, 2011; Prensner and Chinnaiyan, 2011).
Even though several lncRNAs have been discovered using
model systems such as yeast, few have been proven to be
involved in cancer-specific phenotypes and few are discovered
to be involved in cancer metastasis (Gupta et al., 2010; Yuan
et al., 2014). Currently, the majority of cancer studies of lncRNAs
have focused on a few candidates (Cheetham et al., 2013), such
as ANRIL (Yap et al., 2010), lncRNA-ATB (Yuan et al., 2014),
PCAT1 (Prensner et al., 2011) in prostate cancer, XIST (Yildirim
et al., 2013) in hematologic cancer, MALAT1 in lung cancer
(Gutschner et al., 2013), and HOTAIR (Gupta et al., 2010) in
breast cancer. These studies have enabled us to understand
lncRNA biology in cancers; however, applying this knowledge
toward therapeutics is the current need. In the present study,
we report upregulation of the lncRNA ceruloplasmin (NRCP) in
ovarian cancer and elucidate its functional roles in cancer cells
in vitro and in vivo. Intriguingly, we show that NRCP-targeted
siRNA using DOPC nanoliposomes significantly reduced tumororts 13, 2395–2402, December 22, 2015 ª2015 The Authors 2395
Figure 1. The ncRNA NRCP Is Upregulated
in Ovarian Cancer
(A) Heatmap showing the clustering of samples
according to expression of ncRNAs.
(B) Table displaying the top five differentially
expressed probes, the probe sequences, and
p values.
(C) Relative expression of NRCP in ovarian tumor
tissues compared with normal ovarian tissue
samples, originally used for the ncRNA array.
(D) Relative expression of NRCP in a large cohort
(n = 219) of ovarian tumor tissues compared with
normal ovarian tissue samples.
(E) Kaplan-Meier overall survival curves for tumor
samples analyzed for low and high NRCP
expression levels (p = 0.008).
(F) Relative NRCP expression in an array of various
normal tissues compared with normal ovary and
ovarian tumor samples.
(G) Western blot analysis of samples from in vitro
translation assay reactions with NRCP expression
plasmid, and also shown are additional lanes of
samples from assays with luciferase-positive
control plasmid, no plasmid, and no tRNA nega-
tive controls.
Data are presented as mean ± SEM of n R 3
experimental groups. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001 (Student’s t test).growth and increased sensitivity to cisplatin in orthotopic mouse
models of ovarian cancer.
RESULTS
NRCP Deregulation in Ovarian Cancer
Using the human NCode Noncoding RNA Array, we carried out a
comparative analysis of lncRNAs in high-grade serous ovarian
cancer (n = 29) and normal ovarian (n = 11) samples. We identi-
fied >1,000 putative or validated lncRNAs that were deregulated
in ovarian cancer tissues compared with normal ovarian tissues
(Figure 1A). The top five differentially regulated probes mapped
to four lncRNAs (Figure 1B) and were validated in the same
clinical samples as those used for the ncRNA array. Two of
these lncRNAs were significantly upregulated in ovarian cancer
samples compared with normal ovarian tissues (Figures 1C
and S1A); levels of the two other lncRNAs differed lesser in
magnitude (Figures S1B and S1C). Next, we identified that the
NC1 probe corresponds to a lncRNA variant of ceruloplasmin
(NRCP). NC2 corresponded to a newly annotated gene that
encodes ROGDI homolog protein (Uniprot: Q9GZN7). Genomi-
cally, NRCP mapped to chromosome 3 (locus 3q23-q25 of
the ceruloplasmin gene). NRCP is a noncoding splice variant of
ceruloplasmin-coding gene that lacks exon 11 from the coding
region and has several nucleotide changes in the 30 end exons
(Data S1).2396 Cell Reports 13, 2395–2402, December 22, 2015 ª2015 The AuthorsWe observed significant upregulation
of NRCP RNA expression (Figure 1D)
and NC2 (Figure S1D) in ovarian tumor
samples (n-218) compared with normal
ovarian tissues. In Kaplan-Meier survivalanalyses, patients with low tumoral NRCP expression had signif-
icantly better overall survival than those with high NRCP expres-
sion (p = 0.008; Figure 1E). However, we observed only amodest
survival benefit in patients whose tumors had altered NC2
expression (p = 0.029; Figure S1E). Upon comparing NRCP
expression in ovarian tumor samples and in an array of normal
tissue samples from various sites in the body, we observed
>10-fold higher NRCP expression in the tumor than in normal
samples from any site (Figure 1F). In a subset of human
ovarian-tumor-derived RNA samples (n = 15), we quantified
mRNA expression of ceruloplasmin. Correlation analysis with
NRCP expression showed a weak positive correlation (r = 0.29;
p = 0.27; Figure S1F). Upon performing in vitro translation assay
using NRCP clones in an expression plasmid and rabbit reticulo-
cyte system, we observed no distinct protein bands with the
NRCP or negative control reactions (Figure 1G). This further
points to the NRCP transcript being noncoding in nature.
NRCP Involvement in Cancer Cell Metabolism
Next, we sought to elucidate the biological functions affected by
NRCP to better understand the role of NRCP in ovarian cancer.
We selected SKOV3 and A2780 ovarian cancer cells for further
studies because of their high NRCP expression (Figure 2A) and
in vivo tumorigenicity. To understand whether this lncRNA is
expressed in additional cancer cell lines, we measured NRCP
expression in breast cancer cell lines. In MDA MB 231 and
Figure 2. The ncRNA NRCP Is Involved in
Regulation of Glycolysis
(A) Relative expression of NRCP in a panel
of ovarian cancer cells compared with HIO180
(a transformed ovarian epithelial cell line).
(B) Relative expression of NRCP in SKOV3 cells
transfected with siNRCP at different time points.
(C) Heatmap plotted on differentially expressed
cDNA probes showing clustering of control siRNA
and siNRCP samples. SKOV3 cells and 48 hr of
siNRCP were used for the cDNA array.
(D) Table depicting top five altered cellular path-
ways and cellular function after NRCP knockdown
in SKOV3 cells. The array data were analyzed
using Ingenuity Pathway Analysis.
(E) Glucose and lactate concentrations in media
collected from SKOV3 cells transfected with
control siRNA and siNRCP at three different time
points (time calculated 48 hr after transfection and
addition of fresh media with 5 mM glucose).
(F and G) Glycolysis flux data measured using
Seahorse Flux analyzer in SKOV3 cells transfected
with siNRCP compared with sicontrol (F), and
HeyA8 cells ectopically expressing NRCP
compared to control plasmid cells (G). Lines
represent addition of (a) glucose, (b) oligomycin,
and (c) 2-deoxy-D-glucose.
(H and I) Metabolites levels in control and siNRCP-
treated cells. Data from intracellular (H) and
conditioned media (I) measured via NMR method
are shown.
Data are presented as mean ± SEM of n R 3
experimental groups. *p % 0.05; **p % 0.01;
***p% 0.001; ****p < 0.0001 (Student’s t test).MCF7 cells, we observed significantly increased expression of
NRCP, which was comparable to the expression observed in
SKOV3 cells (Figure S2A).
Next, we identified two siRNA sequences specific to NRCP
(siNRCPs), which reduced its expression by >90% (Figure 2B).
We observed no change in the expression of the coding compart-
ment of the ceruloplasmin gene (Figure S2B). From the cDNA array
of RNA samples isolated from siNRCP- and sicontrol-treated
SKOV3 cells, we observed >2,000 significant gene expression
changes (p<0.01) followingsiNRCPtreatmentcomparedwithcon-
trol treatment (Figure 2C). Data were analyzed through the use of
QIAGEN’s Ingenuity Pathway Analysis (QIAGEN; http://www.
ingenuity.com). Top altered cellular pathways were the glycolysis,
cellular respiration, and glucosemetabolism pathways (Figure 2D,
top). The cellular functions most altered by siNRCP were cellular
movement, death, and survival functions (Figure 2D, bottom).
After knockdown of NRCP, significant decreases in glucose
uptake and decreases in amount of lactate production were
observed (Figures 2E and S2C). Parallel with these data, signifi-Cell Reports 13, 2395–2402, Decant decreases in glycolytic flux (ECAR)
were observed in SKOV3 and A2780 cells
treated with siNRCP compared to control
cells (Figures 2F and S2D). Conversely,
upon overexpression of NRCP, HeyA8
cells showed significant increase inECAR (Figure 2G), indicative of increased glycolysis in these
cells. There was significant increase in basal respiration and
ATP-synthase-dependent respiration in siNRCP—compared to
control-treated cells (Figure S2E). Measurement of metabolites
in cancer cells (intracellular) and conditioned media after
silencing NRCP showed a significant reduction in several metab-
olites compared to controls (Figures 2H and 2I). Among the
metabolites changed, lactate showed the greatest decrease
(>40%; Figures 2H and 2I). This further confirmed the reduction
of glycolysis-mediated metabolites because pyruvate acts as an
important intermediate for TCA cycle progression.
Biological Functions Involving NRCP in Ovarian Cancer
Our observations frommicroarray data analysis showed that cell
death, survival, growth, and proliferation are the main cellular
functions affected by NRCP silencing (Figure 2D). To understand
this potential link between reversal of metabolism, reduced tu-
mor growth, and NRCP, we carried out cellular functional assays
after silencing NRCP in SKOV3 and A2780 ovarian cancer cells.cember 22, 2015 ª2015 The Authors 2397
Figure 3. Silencing NRCP Decreases Can-
cer Cell Growth and Metastasis
(A and B) Proliferation measured as percentage of
EdU incorporation (A) and apoptosis measured via
annexin V staining (B) in control siRNA- and
siNRCP-treated SKOV3 cells measured 72 hr after
transfection.
(C) Percentages of apoptotic cells in control
siRNA- and siNRCP-treated SKOV3 cells with or
without an IC50 dose of cisplatin.
(D) Effect of in vivo silencing of NRCP in an SKOV3
orthotopic model of ovarian cancer. Aggregate
tumor weights are shown in mice treated with
control siRNA, siNRCP, and combinations with
cisplatin (n = 10 per group).
(E) Average numbers of distant metastatic nodules
across the four groups. Representative pictures of
tumor burden in each treatment group are shown
in side panel.
(F and G) Immunohistochemistry data illustrating
apoptosis via caspase 3+ staining (F) and prolif-
eration via the Ki67 index (G) across the four
groups of tumors harvested.
(H) Relative expression of NRCP in tumors har-
vested from individual groups of mice treated with
control siRNA, siNRCP, and combinations with
cisplatin.
(I) Levels of metabolite in tumor tissue samples
treated with control siRNA or siNRCP; data were
obtained via NMR method.
Data are presented as mean ± SEM of n R 3
experimental groups. *p < 0.05; **p < 0.01;
***p < 0.001 (Student’s t test).There was a significant reduction in 5-ethynyl-20-deoxyuridine
(EdU) incorporation in SKOV3 and A2780 cells transfected with
siNRCP compared with sicontrol-treated cells (see Figure 3A
for SKOV3 and Figure S3A for A2780). Annexin V staining
showed significantly more apoptosis in siNRCP-treated SKOV3
cells than in sicontrol-treated cells (see Figure 3B for SKOV3
and Figure S3B for A2780). Cell-cycle analysis of SKOV3 cells
treated with siNRCP revealed a significant reduction of cells in
the S phase and accumulation of cells at G2 compared with con-
trol-treated cells, suggesting an increase in cellular apoptosis
following G2 arrest (Figure S3C). Cells treated with siNRCP
showed significant reduction in cyclin B1, suggesting G2 cell-cy-
cle arrest, whereas CDK1 showed no such change (Figure S3D).
Consistent with the above data, we observed a significant reduc-
tion in cell viability in siNRCP-treated SKOV3 cells compared
with sicontrol-treated cells (Figure S3E).
Because silencing NRCP significantly reduced cell viability, we
next askedwhether siNRCPwould be evenmore effective in com-2398 Cell Reports 13, 2395–2402, December 22, 2015 ª2015 The Authorsbinationwithcommonlyusedchemothera-
peuticagents forovariancancer treatment.
Weobservedasignificant shift insensitivity
of SKOV3 cells to cisplatin after NRCP
gene knockdown (Figure S3F); however,
we did not see sensitization to docetaxel
with NRCP knockdown (Figure S3F). To
validate this observation, we treatedSKOV3 cells with siNRCP, cisplatin, or siNRCP plus cisplatin
and performed an annexin V apoptosis assay. Apoptosis was
increased in the cells treatedwith siNRCP combinedwith cisplatin
than in those treated with sicontrol, siNRCP alone, or cisplatin
alone (Figures 3C and S3G). Conversely, we observed decreased
cell apoptosis and increased cell proliferation in cells ectopically
expressing NRCP compared to control cells (Figure S3H).
Considering that cellular movement pathways were also
affected by NRCP gene knockdown (Figure 2D), we assessed
the migration and invasion potential of SKOV3 cells treated
with siNRCP. Consistent with the findings from the microarray
analyses, knockdown of NRCP significantly reduced migration
and invasion of SKOV3 cells (Figure S3J).
In Vivo Effects of NRCP Silencing in Ovarian Cancer
Models
Next, we evaluated the effects of NRCP silencing on tumor
growth and metastasis in vivo in a murine orthotopic model of
Figure 4. NRCP Regulates Cancer Cell
Glycolysis by Binding to STAT1
(A) Relative expression of NRCP, cytoplasmic
control RNAs 18S and b-actin and nuclear control
RNAs U6, MALAT1, and 5.8S rRNA in RNA sam-
ples isolated from nuclear and cytoplasmic cell
fractionations of SKOV3 cells.
(B) Western blot data from GSH-agarose immu-
noprecipitation of protein lysates from SKOV3
cells transfected with pMS2-control and pMS2-
NRCP plasmid. Membranes were probed for RNA
pol II and STAT1 using corresponding antibodies.
(C) Data show expression of NRCP in HeyA8-pCL-
NRCP cells transfected with siRNA against NRCP
(right). Western blot data show binding of RNA pol
II and STAT1 (left). HeyA8-pCL-NRCP cells were
treated with sicontrol and siNRCP; cell lysates
were subjected to immunoprecipitation using an
anti-STAT1 antibody.
(D) RIP assay qPCR data showing significant fold
enrichment in NRCP binding to STAT1 and RNA
pol II. Data normalized to IgG isotype control
immunoprecipitation.
(E and F) RNA expression of key glycolysis
pathway proteins GPI, ALDOA, and ALDOC in
cells transfected with siRNA against NRCP (E) or
HeyA8 cells ectopically expressing NRCP, with
and without siNRCP transfected (F), compared to
respective sicontrols.
(G) Summary of study showing mechanism by
which NRCP mediates increased glycolysis in
cancer.
Data are presented as mean ± SEM of n R 3
experimental groups. *p < 0.05; **p < 0.01;
***p < 0.001 (Student’s t test).ovarian cancer using intra-ovarian injection of SKOV3 cells.
There was significant reduction in gross tumor weight in the
DOPC-siNRCP-treated mice compared to DOPC-sicontrol-
treated group (Figure 3D). In addition, compared to the mice
treated with sicontrol, mice treated with siNRCP and cisplatin
combination showed significant tumor reduction and metastasis
(Figures 3D and 3E). Immunohistochemistry staining for cleaved
caspase-3 in tumor tissues from all four groups showed signifi-
cantly increased apoptosis in the groups treated with siNRCP,
cisplatin, or siNRCP plus cisplatin compared with the control
group (Figure 3F). In addition, quantitation of proliferation via
the Ki67 index showed significant reductions in cell proliferation
in the groups treated with siNRCP, cisplatin, or siNRCP plus
cisplatin compared with the sicontrol group (Figure 3G). NRCP
expression in the tumors from siNRCP groups was reduced by
>75% compared to tumors from sicontrol group (Figure 3H).
Metabolite analyses from these samples revealed significant
reduction in lactate levels in the tumors treated with siNRCPCell Reports 13, 2395–2402, Decompared to sicontrol (Figure 3I), further
supporting the in vitro observations.
We also evaluated the in vivo effects of
NRCP silencing using the ovarian cancer
cell line A2780. We observed tumor size
reduction and fewer metastatic nodulesin A2780 tumor-bearing mice treated with siNRCP, cisplatin,
or siNRCP plus cisplatin compared with the control group
(Figures S3K–S3N), as observed in the in vivo NRCP-silencing
study with SKOV3 cells.
Mechanisms Underlying the NRCP-Glycolysis Link in
Cancer Cells
Using nuclear and cytoplasmic fractionation from cell lysates
and quantification of RNA abundance using qRT-PCR, we
observed significant enrichment of NRCP in the nucleus
compared to the cytoplasmic fraction in SKOV3, A2780, and
HeyA8 cells with ectopic expression of NRCP (Figures 4A,
S4A, and S4B). Using the bait system (Yoon et al., 2012) of
MS2 protein-MS2 RNA affinity interactions and mass spectrom-
etry analysis, we identified 190 unique proteins binding to
NRCP. From the analysis of their localization, cellular functions,
and potential involvement in glycolysis pathways, we identified
STAT1 as a key candidate potentially binding to NRCPcember 22, 2015 ª2015 The Authors 2399
(Table S1; Figure S4C). The role of STAT1 in modulating cancer
cell metabolismwas suggested earlier (Pitroda et al., 2009); how-
ever, mechanisms were not identified. Immunoprecipitation
using GSH-conjugated agarose beads and western blotting
revealed significant binding of NRCP to STAT1 (Figure 4B).
Because STAT1 transcription programming involves binding of
RNA pol II, we checkedwhether NRCP facilitates the interactions
between STAT1 and RNA pol II. Upon probing the western blot
described above with anti-RNA pol II, we observed significant
binding of RNA pol II to MS2-NRCP (Figure 4B). Next, we ectop-
ically expressed NRCP in HeyA8 cells and used siRNAs against
NRCP todecrease the expression, followedby immunoprecipita-
tion with anti-STAT1. In the sicontrol-treated HeyA8-NRCP cells,
upon anti-STAT1 pull-down and western blotting for RNA pol II,
we identified clear binding of STAT1 with RNA pol II (Figure 4C).
Interestingly, we observed significant decrease in RNA pol II
binding to STAT1 upon silencing NRCP (Figure 4C), suggesting
the role of NRCP as an intermediate molecule facilitating
STAT1-RNA pol II interactions. In a different approach, we per-
formed RNA-immunoprecipitation (RIP) assay using anti-STAT1
and anti-RNA pol II antibodies in SKOV3 cells. NRCP showed
significant enrichment in binding to STAT1 and RNA pol II in
RIPRNAsamples (Figure 4D), further supporting the link between
NRCP and these two proteins. We usedMALAT1 and U1 as con-
trols for RIP reactions (Figures 4D and 4E). After silencing or
rescuing NRCP in cancer cells, we tested expression of key
glycolysis pathwaymolecules suggested from the genomic array
of siNRCP-treated SKOV3 cells (Ingenuity Pathway Analysis;
Data S2). Significant reduction in glucose-6-phosphate isom-
erase (GPI), ALDOA, and ALDOC was observed after silencing
NRCP in SKOV3 or A2780 cells (Figure 4E). Conversely, upon
rescue of NRCP expression in HeyA8 cells, we observed signifi-
cant increase in the expression of these molecules compared to
control cells (Figure 4F). Upon silencing STAT1 in the cells ectop-
ically expressing NRCP, we observed significant reduction in the
expression of GPI, ALDOA, and ALDOC (Figure 4F), further
strengthening the role played by NRCP-STAT1 axis in regulating
glycolysis. In summary, our data show that NRCP is involved in
glycolysis regulation in cancer cells through NRCP acting as an
intermediatemolecule betweenSTAT1andRNApol II, enhancing
their interactions, leading to increased STAT1 transcriptional
programming (Figure 4G).
DISCUSSION
In this study, we elucidated the role of the lncRNANRCP inmeta-
bolic alterations in cancer cells. By profiling ncRNA expression in
human normal ovaries and ovarian tumors, we identified NRCP
as the top-upregulated lncRNA in ovarian cancer. We report
that silencing NRCP significantly decreases glycolysis and in-
creases mitochondrial respiration in cancer cells. This ultimately
led to enhanced cancer cell apoptosis and decreased cell prolif-
eration. Using orthotopic ovarian cancer mouse models, we
further demonstrated the profound reduction in primary tumor
growth and cancer metastasis following delivery of nanolipo-
some-delivered siNRCP to tumors.
Studies have shown that cancer cells rely on glycolysis for en-
ergy production, whereas normal cells rely on the oxidative2400 Cell Reports 13, 2395–2402, December 22, 2015 ª2015 The Aupathway (Warburg, 1956; Vander Heiden et al., 2009). Inhibition
of lactate production is suggested to have significant therapeutic
benefits in cancer (Doherty andCleveland, 2013). In a recent lung
cancer study, reversal of Warburg effect by inhibition of EGFR
signaling resulted in significant tumor reduction (De Rosa et al.,
2015) and highlights the potential for the therapeutic targeting of
glycolysis. Currently, there is limited data on role of lncRNAs in
regulating cancer metabolism. Whereas Li et al. (2014) have
recently reported the role of the lncRNA UCA1 in hexokinase
dysfunction, this study was limited to in vitro observations. A
lncRNA specific to prostate cancer called PCGEM1 was shown
to be involved in promoting cancer cell metabolism mediated by
binding of this lncRNA to MYC transcription factor and activation
of downstream genes (Hung et al., 2014). These suggest evolving
roles of lncRNAs in cancer cell metabolism and showgreat prom-
ise toward use of this knowledge for therapeutic applications.
The use of siRNA-based approaches for silencing these
chemically non-targetable genes is suggested by several
studies. One of the recent developments in the delivery of siRNA
is the liposomal carrier DOPC, which enables efficient delivery of
siRNA molecules to the tumor microenvironment (Nishimura
et al., 2013; Wu et al., 2014). Preclinical studies by our group
have shown targeting EphA2 in ovarian cancer (Kamat et al.,
2009) using the same approach, which is currently entering clin-
ical trials (NCT01591356). In the present study, we used a similar
approach to target a lncRNA in vivo using a siRNA against NRCP
incorporated in a DOPC liposomal carrier.
In summary, our findings reveal a novel role of lncRNAs in can-
cer metabolism. Our study provides a basis for further develop-
ment and application of RNAi-based therapeutic approaches to
target lncRNAs and shows an expanded potential for siRNA-
based therapeutics for more-effective treatment of diseases
such as cancer.
EXPERIMENTAL PROCEDURES
Cell Line Maintenance and siRNA Transfections
All the cell lines used were obtained from the ATCC and were maintained in
RPMI1640 medium supplemented with 10%–15% fetal bovine serum and
0.1%gentamicin sulfate (Gemini Bio-Products) in 5%CO2 at 37
C. All cell lines
were routinely tested to confirm the absence of Mycoplasma, and all in vitro
experiments were conducted with 60%–80% confluent cultures. For detailed
procedure, please refer to Supplemental Experimental Procedures.
In Vivo Models
Female athymic nude mice were purchased from Taconic Farms. These ani-
mals were cared for according to guidelines set forth by the American Associ-
ation for Accreditation of Laboratory Animal Care and the United States Public
Health Service policy on Humane Care and Use of Laboratory Animals. All
mouse studies were approved and supervised by The University of Texas MD
Anderson Cancer Center Institutional Animal Care and Use Committee. All
mice usedwere 8–12weeks old at the time of treatment. The orthotopicmouse
models of ovarian cancerwere developed as described previously (Pecot et al.,
2013; Pradeep et al., 2014). For all experiments, mice were randomly divided
and treatedwith intraperitoneal administration of siRNA incorporated in neutral
DOPC nanoliposomes prepared as previously described (Kamat et al., 2009;
Nishimura et al., 2013; Pecot et al., 2013; Pradeep et al., 2014). For detailed
procedure, please refer to the Supplemental Experimental Procedures.
Identification of NRCP-Binding Proteins
To identify potential protein-binding partners of NRCP, we used the MS2-
tagged RNA affinity purification technique (Yoon et al., 2012). Briefly, wethors
cloned full-length NRCP into pMS2 plasmid containing MS2 repeats. SKOV3
cells were transfected with pMS2 plasmids (control or NRCP) and MS2-GST
plasmids (a fusion protein recognizing the MS2 RNA hairpins), and cell lysates
were prepared according to previously described protocol (Yoon et al., 2012).
MS2 protein-MS2 RNA-NRCP complex along with associated proteins were
immunoprecipitated using GSH-conjugated agarose beads. We eluted protein
complex from agarose beads and subjected the samples to mass spectrom-
etry analysis at MD Anderson Cancer Center Proteomics core facility. Identi-
fied proteins from MS/MS analysis were compared between pMS2-control
and pMS2-NRCP to identified NRCP-bound proteins. Using Ingenuity
Pathway Analysis, we characterized these proteins according to their cellular
localization and functions to identify top candidates to confirm the interactions
with NRCP.
Microarrays and Data Analysis
Total RNA was extracted from the ovarian tumor samples and normal ovarian
tissues using the mirVana RNA Isolation kit (Life Technologies). Expression
levels of ncRNAs were profiled using NCode Noncoding RNA Array (Invitro-
gen). Microarray results were analyzed by using GeneSpring GX software,
version 12.6 (Agilent Technologies). For detailed procedure, please refer to
Supplemental Experimental Procedures.
Immunostaining, Cell Proliferation, Cell Viability, Cell Cycle, and
Apoptosis Assays
For immunohistochemical analyses, 5-mm paraffin sections of tumor tissues
were used for the detection of the proliferation marker Ki67 and the apoptosis
marker cleaved caspase-3. For Ki67 and cleaved caspase-3 staining, the
numbers of tumor cells that were positive for expression were counted. Modi-
fied Boyden chambers (Coster) coated with 0.1% gelatin or extracellular ma-
trix components were used to measure migration and invasion, respectively.
Post assay, cells were fixed and stained, and then cells from five random fields
were counted using light microscopy. For detailed procedure, please refer to
Supplemental Experimental Procedures.
In Vitro Translation Assay
NRCP-pCL-Neo with full-length NRCP and luciferase-positive control
plasmid was used for in vitro translation assays using the TnT Quick Coupled
Transcription/Translation System (Promega) with 1 mM methionine and
Transcend Biotin-Lysyl-tRNA (Promega) according to the manufacturer’s in-
structions. For detailed procedure, please refer to Supplemental Experimental
Procedures.
Measurement of Glycolysis and Respiration Rate
The Seahorse Extracellular Flux Analyzer XF96 (Seahorse Bioscience) was
used to measure oxygen consumption rate upon silencing NRCP using
siRNAs. For glycolysis measurements, we added glucose, oligomycin, and
deoxy-glucose to measure basal flux rates glycolytic capacity and to inhibit
glycolysis, respectively. For detailed procedure, please refer to the Supple-
mental Experimental Procedures.
RIP Assays
RIP assays were performed using aMillipore EZ-Magna RIP RNA-Binding Pro-
tein Immunoprecipitation kit (Millipore; 17-701) according to the manufac-
turer’s instructions. For detailed procedure, please refer to the Supplemental
Experimental Procedures.
NMR Measurement of Metabolites
For the measurement of metabolite in media studies, we collected condi-
tioned media from cells treated with sicontrol and siNRCP for 48 hr. Cell
pellets or tumor tissue samples were used for measurement of intracellular
metabolite levels. Analyses of samples were done using nuclear magnetic
resonance (NMR) spectroscopy. For in vitro measurements, cell counts
were used to normalize the data. For in vivo tumor samples, data normalized
to tissue weight and intratumor level of NRCP measured by qPCR. For
detailed procedure, please refer to the Supplemental Experimental
Procedures.Cell RepACCESSION NUMBERS
The accession numbers for the data reported in this paper are GEO:
GSE74447 and GEO: GSE74448.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and two data files and can be found with this article on-
line at http://dx.doi.org/10.1016/j.celrep.2015.11.047.
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